J&J Inks $785M Deal with Sail Biomedicines for In Vivo CAR-T, Secures $2.58B Buyout Option
JNJ sits 62% above its 52-week low of $164.23.
Summary
Johnson & Johnson is making a major push into next-generation cell therapy, committing $785 million upfront to collaborate with Sail Biomedicines on in vivo CAR-T programs for autoimmune diseases. The deal includes a $465 million equity stake and an exclusive option to acquire Sail outright for $2.58 billion, with an added payment of $2.58 billion subject to the decision to exercise the option. There are also contingent payments of $140 million if certain development milestones are achieved. This follows a strong Q2 and a recent $5.5 billion talc settlement, showing J&J is actively deploying capital to strengthen its pipeline. The collaboration targets immune reset—a potentially curative approach—and expands J&J's capabilities beyond its existing oncology CAR-T franchise. Management expects the deal to dilute adjusted EPS by $0.18 in 2026 and $1.28 in 2027, a modest near-term cost for a platform that could reshape treatment of complex immune-mediated diseases.
At the time of this announcement, JNJ was trading at $265.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $639.9B. The 52-week trading range was $164.23 to $274.90. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.